Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
companyunderground
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Novartis
Novartis
Novartis eyes $1B Lutathera acceleration with trial win in newly diagnosed neuroendocrine tumors
Fierce Pharma
Fri, 01/19/24 - 11:19 am
Novartis
Lutathera
radiopharmaceuticals
neuroendocrine tumors
Novartis Ends Phase III Peanut Allergy Trial in Another Flop for Potential Xolair Successor
BioSpace
Thu, 01/18/24 - 10:58 am
Novartis
clinical trials
peanut allergy
ligelizumab
Amgen Emerges as Potential Cytokinetics Suitor as Novartis Pulls Away: Reports
BioSpace
Fri, 01/12/24 - 09:59 am
Novartis
Cytokinetics
Amgen
M&A
Novartis drops pursuit of Cytokinetics - source
Reuters
Thu, 01/11/24 - 08:41 pm
Novartis
Cytokinetics
M&A
Novartis in advanced talks to buy Cytokinetics
Reuters
Mon, 01/8/24 - 10:29 pm
Novartis
Cytokinetics
M&A
aficamten
Novartis’ Scemblix meets primary endpoints in Phase III leukemia trial
Clinical Trials Arena
Mon, 01/8/24 - 11:41 am
Novartis
clinical trials
Scemblix
asciminib
CML
Novartis dances into JPM with $250M Calypso buyout, $185M RNAi alliance
Fierce Biotech
Mon, 01/8/24 - 11:33 am
Novartis
Calypso
M&A
RNAi
JPMHC 2024
Alphabet’s Isomorphic stacks two new deals with Lilly, Novartis worth nearly $3B ahead of JPM
Fierce Biotech
Sun, 01/7/24 - 04:19 pm
Alphabet
Isomorphic
Eli Lilly
Novartis
Why Novartis rebranded to tell patients, ‘We’re with you’
Medical Marketing and Media
Fri, 01/5/24 - 09:53 am
Novartis
rebranding
Novartis, Voyager launch another gene therapy mission with $100M upfront deal
Fierce Biotech
Tue, 01/2/24 - 10:05 am
Novartis
gene therapy
Voyager Therapeutics
Huntington's disease
SMA
Roche, Novartis move Xolair closer to FDA finish line for food allergies
Fierce Pharma
Tue, 12/19/23 - 11:10 pm
Roche
FDA
Xolair
food allergies
Novartis
Novartis unveils promising Fabhalta data for C3 glomerulopathy indication
Medical Marketing and Media
Tue, 12/12/23 - 09:56 am
Novartis
clinical trials
Fabhalta
iptacopan
C3 glomerulopathy
Novartis gears up for label expansion for Kisqali with Phase III results
Clinical Trials Arena
Mon, 12/11/23 - 11:18 am
Novartis
Kisqali
FDA
clinical trials
early breast cancer
breast cancer
ASH: As Novartis enters PNH market, AstraZeneca shows longer term effect of its latest contender
Fierce Biotech
Mon, 12/11/23 - 10:07 am
ASH 2023
AstraZeneca
Novartis
PNH
danicopan
Novartis hit with FDA letter detailing 'significant' Kymriah manufacturing shortfalls
Fierce Pharma
Thu, 12/7/23 - 10:08 am
Novartis
FDA
Kymriah
CAR-T
drug manufacturing
Daiichi Sankyo unit claims $182m in Novartis patent dispute
Pharmaphorum
Wed, 12/6/23 - 10:31 am
Daiichi Sankyo
Novartis
Plexxikon
legal
patents
Tafinlar
Novartis receives FDA approval for Fabhalta to treat PNH in adults
Pharmaceutical Business Review
Wed, 12/6/23 - 10:25 am
Novartis
FDA
Fabhalta
iptacopan
PNH
paroxysmal nocturnal hemoglobinuria
Novartis sees brighter sales future as R&D revamp continues
BioPharma Dive
Tue, 11/28/23 - 11:36 pm
Novartis
R&D
Novartis pays Legend $100M upfront to give solid tumor CAR-T the T-Charge treatment
Fierce Biotech
Mon, 11/13/23 - 11:55 am
Novartis
Legend Biotech
CAR-T
T-Charge
solid tumors
Novartis’ urticaria drug meets all endpoints in Phase III trials
Clinical Trials Arena
Fri, 11/10/23 - 10:05 am
Novartis
remibrutinib
chronic spontaneous urticaria
clinical trials
Pages
« first
‹ previous
…
4
5
6
7
8
9
10
11
12
…
next ›
last »